Folic Acid ( DrugBank: Folic acid )
5 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 2 |
| 46 | 悪性関節リウマチ | 51 |
| 49 | 全身性エリテマトーデス | 1 |
| 84 | サルコイドーシス | 2 |
| 296 | 胆道閉鎖症 | 1 |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
Showing 1 to 2 of 2 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01238926 (ClinicalTrials.gov) | May 2008 | 9/11/2010 | Vitamin B6, B12, Folic Acid and Exercise in Parkinson's Disease | Effects of Vitamin Supplementation and Strength Training in Parkinson's Disease | Parkinson's Disease | Dietary Supplement: PD vitamin supplementation;Other: PD exercise intervention;Other: PD vitamin + exercise Dietary Supplement: PD vitamin supplementation;Other: PD exercise intervention;Other: PD vitamin + e ... | New York Institute of Technology | Stony Brook University | Active, not recruiting | 50 Years | 80 Years | Both | 40 | N/A | United States |
| 2 | NCT00853879 (ClinicalTrials.gov) | December 2006 | 26/2/2009 | An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's Disease An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acidand L-methylfolate in Par ... | An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's Disease An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acidand L-methylfolate in Par ... | Parkinson's Disease | Dietary Supplement: Folic Acid, Vitamin B6, Vitamin B12;Dietary Supplement: B6, B12, L-methylfolate;Dietary Supplement: B6, B12, Placebo Dietary Supplement: Folic Acid, Vitamin B6, Vitamin B12;Dietary Supplement: B6, B12, L-methylfolate; ... | North Shore Long Island Jewish Health System | NULL | Terminated | 30 Years | N/A | Both | 150 | N/A | United States |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
Showing 1 to 10 of 51 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2200055292 | 2022-01-04 | 2022-01-05 | Correlation between the changes of serum cytokines and immune cell subsets levels and curative effect in patients with active rheumatoid arthritis before and after Yisaipu treatment Correlation between the changes of serum cytokines and immune cell subsets levels and curative effec ... | Correlation between the changes of serum cytokines and immune cell subsets levels and curative effect in patients with active rheumatoid arthritis before and after Yisaipu treatment Correlation between the changes of serum cytokines and immune cell subsets levels and curative effec ... | Rheumatoid Arthritis | Experimental group:Yisaipu combined with methotrexate and folic acid; | Peking University People's Hospital | NULL | Recruiting | 18 | 65 | Both | Experimental group:140; | Phase 4 | China |
| 2 | ITMCTR2100005379 | 2021-12-01 | 2021-12-06 | Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLing Zhiwang Prescription Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLi ... | Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLing Zhiwang Prescription Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLi ... | Rheumatism | The treatment group:Simiaoxiaoling Zhiwang Decoction (granule) + methotrexate + folic acid tablets;The control group:methotrexate + folic acid tablets; The treatment group:Simiaoxiaoling Zhiwang Decoction (granule) + methotrexate + folic acidtablets;Th ... | Yunnan Hospital of Traditional Chinese Medicine | NULL | Recruiting | 18 | 70 | Both | The treatment group:36;The control group:36; | China | |
| 3 | ChiCTR2100053999 | 2021-12-01 | 2021-12-06 | Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLing Zhiwang Prescription Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLi ... | Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLing Zhiwang Prescription Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLi ... | Rheumatism | Experimental group:Simiaoxiaoling Zhiwang Decoction (granule) + methotrexate + folic acid tablets;Control group:methotrexate + folic acid tablets; Experimental group:Simiaoxiaoling Zhiwang Decoction (granule) + methotrexate + folic acidtablets;Con ... | Yunnan Hospital of Traditional Chinese Medicine | NULL | Recruiting | 18 | 70 | Both | Experimental group:36;Control group:36; | China | |
| 4 | ChiCTR2100054305 | 2021-12-01 | 2021-12-13 | Observation on the clinical efficacy of Jiawei Qianyang Fengsui Dan in the treatment of RA with mixed syndrome of cold and heat Observation on the clinical efficacy of Jiawei Qianyang Fengsui Dan in the treatment of RA with mixe ... | Observation on the clinical efficacy of Jiawei Qianyang Fengsui Dan in the treatment of RA with mixed syndrome of cold and heat Observation on the clinical efficacy of Jiawei Qianyang Fengsui Dan in the treatment of RA with mixe ... | Rheumatoid Arthritis | Treatment group:Modified Qianyang Fengsui Dan + Methotrexate Tablets + Folic Acid Tablets;Control group:Methotrexate + Folic Acid; Treatment group:Modified Qianyang Fengsui Dan + Methotrexate Tablets + Folic AcidTablets;Control gro ... | Yunnan Provincial Hospital of Traditional Chinese Medicine | NULL | Recruiting | 18 | 70 | Both | Treatment group:36;Control group:36; | China | |
| 5 | ITMCTR2100004321 | 2021-01-25 | 2021-01-25 | Observation on the clinical effect of treating rheumatoid arthritis based on the theory of kidney deficiency and cold coagulation Observation on the clinical effect of treating rheumatoid arthritis based on the theory of kidney de ... | Observation on the clinical effect of treating rheumatoid arthritis based on the theory of kidney deficiency and cold coagulation Observation on the clinical effect of treating rheumatoid arthritis based on the theory of kidney de ... | Rheumatoid Arthritis | control group:Methotrexate tablets + Folic acid tablets;experimental group:Fuzi Guizhi Decoction granules+Methotrexate tablets + Folic acid tablets; control group:Methotrexate tablets + Folic acidtablets;experimental group:Fuzi Guizhi Decoction gran ... | The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine | NULL | Recruiting | 18 | 65 | Both | control group:36;experimental group:36; | China | |
| 6 | ChiCTR2100042659 | 2021-01-25 | 2021-01-25 | Observation on the clinical effect of treating rheumatoid arthritis based on the theory of kidney deficiency and cold coagulation Observation on the clinical effect of treating rheumatoid arthritis based on the theory of kidney de ... | Observation on the clinical effect of treating rheumatoid arthritis based on the theory of kidney deficiency and cold coagulation Observation on the clinical effect of treating rheumatoid arthritis based on the theory of kidney de ... | Rheumatoid Arthritis | experimental group:Fuzi Guizhi Decoction granules+Methotrexate tablets + Folic acid tablets;control group:Methotrexate tablets + Folic acid tablets; experimental group:Fuzi Guizhi Decoction granules+Methotrexate tablets + Folic acidtablets;control g ... | The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine | NULL | Recruiting | 18 | 65 | Both | experimental group:36;control group:36; | China | |
| 7 | ITMCTR2100004302 | 2021-01-21 | 2021-01-21 | Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis with heat syndrome and its effect on drug resistance gene Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis wit ... | Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis with heat syndrome and its effect on drug resistance gene Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis wit ... | difficult-to-treat rheumatoid arthritis | The normal group:No special treatment;Refractory (control group):Methotrexate + folic acid tablets + adalimumab + simulant;Refractory (trial group):Methotrexate + folic acid tablets + Adalimumab + Qingre Tongluo Prescription; Primary untreated group:Do not give any treatment, only before treatment for blood, the group does not consider follow-up treatment, recommended patients to seek medical advice, follow the doctor 's orders;Therapeutic effective group:Continue the original treatment plan; The normal group:No special treatment;Refractory (control group):Methotrexate + folic acidtablets + ... | Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University o ... | NULL | Recruiting | 18 | 70 | Both | The normal group:15;Refractory (control group):15;Refractory (trial group):15; Primary untreated group:15;Therapeutic effective group:15; | China | |
| 8 | ChiCTR2100042440 | 2021-01-21 | 2021-01-21 | Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis with heat syndrome and its effect on drug resistance gene Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis wit ... | Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis with heat syndrome and its effect on drug resistance gene Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis wit ... | difficult-to-treat rheumatoid arthritis | The normal group:No special treatment; Primary untreated group:Do not give any treatment, only before treatment for blood, the group does not consider follow-up treatment, recommended patients to seek medical advice, follow the doctor 's orders;Therapeutic effective group:Continue the original treatment plan;Refractory (trial group):Methotrexate + folic acid tablets + Adalimumab + Qingre Tongluo Prescription;Refractory (control group):Methotrexate + folic acid tablets + adalimumab + simulant; The normal group:No special treatment; Primary untreated group:Do not give any treatment, only befor ... | Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University o ... | NULL | Recruiting | 18 | 70 | Both | The normal group:15; Primary untreated group:15;Therapeutic effective group:15;Refractory (trial group):15;Refractory (control group):15; | China | |
| 9 | ITMCTR2100004288 | 2021-01-19 | 2021-01-19 | Effect of Wenyang Tongluo Recipe on Cold Syndrome of Rheumatoid Arthritis and Drug Resistant Gene | Effect of Wenyang Tongluo Recipe on Cold Syndrome of Rheumatoid Arthritis and Drug Resistant Gene | Rheumatoid arthritis | Observation group:Methotrexate + folic acid tablets + Adamumab + Wenyang Tongluo Recipient;Primary untreated group:No treatment was given, only blood was drawn before treatment, and follow-up treatment was not considered in this group. Patients were advised to seek medical treatment by themselves and follow the doctor's advice;Therapeutic effective group:Continue with the original regimen;The control group:Methotrexate + folic acid tablets + adamulizumab + simulation agent;The normal group:No special treatment will be given; Observation group:Methotrexate + folic acidtablets + Adamumab + Wenyang Tongluo Recipient;Primary un ... | Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine) Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University ... | NULL | Recruiting | 18 | 70 | Both | Observation group:15;Primary untreated group:15;Therapeutic effective group:15;The control group:15;The normal group:15; | China | |
| 10 | ITMCTR2100004290 | 2021-01-19 | 2021-01-19 | Effect of Huangqijishengtang on deficiency of liver and kidney in rheumatoid arthritis and its effect on bone metabolism Effect of Huangqijishengtang on deficiency of liver and kidney in rheumatoid arthritis and its effec ... | Effect of Huangqijishengtang on deficiency of liver and kidney in rheumatoid arthritis and its effect on bone metabolism Effect of Huangqijishengtang on deficiency of liver and kidney in rheumatoid arthritis and its effec ... | rheumatoid arthritis | Intervention group:Folic Acid;control group:Calcitriol Soft Capsules;Intervention group:Calcitriol Soft Capsules;control group:MTX;control group:Folic Acid;Intervention group:Huangqijishengtang+Calcitriol Soft Capsules+MTX;Intervention group:MTX;control group:Simulator of Huangqijishengtang;;12122112 Intervention group:Folic Acid;control group:Calcitriol Soft Capsules;Intervention group:Calcitriol S ... | The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine | NULL | Recruiting | 18 | 70 | Both | Intervention group:38;control group:38;Intervention group:38;control group:38;control group:38;Intervention group:38;Intervention group:38;control group:38; | China |
49. 全身性エリテマトーデス
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
Showing 1 to 1 of 1 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00470522 (ClinicalTrials.gov) | June 1995 | 2/5/2007 | Study of Methotrexate in Lupus Erythematosus | A Canadian Multicenter, Randomized, Double-Blind Placebo-Controlled Study of Methotrexate and Folic Acid in Systemic Lupus Erythematosus: A Phase III Trial. A Canadian Multicenter, Randomized, Double-Blind Placebo-Controlled Study of Methotrexate and Folic ... | Systemic Lupus Erythematosus | Drug: Methotrexate and folic acid | University Health Network, Toronto | McGill University Health Center | Completed | 18 Years | N/A | Both | 86 | Phase 3 | Canada |
84. サルコイドーシス
臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169
Showing 1 to 2 of 2 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs011210048 | 05/11/2021 | 05/11/2021 | Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial | Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial - CHASM CS- RCT | Cardiac Sarcoidosis Cardiac Sarcoidosis | Subjects meeting the study inclusion/exclusion criteria will be randomized equally to receive either: 1. Prednisone 0.5 mg kg/day for 6-months (MAX dose 30 mg per day) or 2. Methotrexate 15-20 mg po, sc, or IM once a week for 6-months + Folic Acid 2 mg OD for 6 months + Prednisone 20 mg day for 1 month, then 10 mg OD for 1 month, then 5 mg OD for one month then STOP Subjects meeting the study inclusion/exclusion criteria will be randomized equally to receive either ... | Toshiyuki Nagai | NULL | Pending | >= 18age old | Not applicable | Both | 194 | Phase 3 | Canada;United States;United Kingdom;Japan |
| 2 | JPRN-jRCTs041180111 | 16/12/2016 | 19/03/2019 | Estimated by FDG PET/CT in Myocardial Sarcoidosis | Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - OMT-CS study | Cardiac sarcoidosis Cardiac sarcoidosis | After using PSL for 6 months, patients were classified by decreasing rate of TLG. If TLG is decreasing over 70%, PSL was prescribed 5mg/day for more 6 months. If TLG is decreasing under 70%, arm A: PSL was prescribed 30mg/day and diminishing PSL 5mg per month for more 6 months arm B: MTX (6mg/week) and folic acid (5mg/week) was prescribed for more 6 months After using PSL for 6 months, patients were classified by decreasing rate of TLG. If TLG is decreasi ... | Murohara Toyoaki | NULL | Complete | >= 20age old | Not applicable | Both | 85 | Phase 3 | Japan |
296. 胆道閉鎖症
臨床試験数 : 71 / 薬物数 : 70 - (DrugBank : 39) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 60
Showing 1 to 1 of 1 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100050992 | 2021-10-08 | 2021-09-10 | Treatment of biliary atresia and prevention of postoperative cholangitis with folic acid: Multicenter clinical study on drug efficacy Treatment of biliary atresia and prevention of postoperative cholangitis with folic acid: Multicente ... | Therapeutic and preventive effect of Folic acid on billiary atresia and postoperative cholangitis | biliary atresia | control group:Conventional therapy;experimental group:Conventional therapy+Folic acid; | Guangzhou Women and Children Medical Center | NULL | Recruiting | 0 | 2 | Both | control group:150;experimental group:150; | China |